Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post...
Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post...
Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post Pounce System Use
surmodics宣布对60名具有急性、亚急性或慢性肢体缺血症状的患者进行了早期子集分析，96.8%的程序性血流恢复，81.7%的受试者在Pounce系统使用后未接受额外的血栓栓塞去除治疗
Early subset analysis of 60 patients with acute, subacute, or chronic symptoms of limb ischemia demonstrated 96.8% procedural flow restoration, with 81.7% of subjects not receiving additional thromboemboli removal treatment post Pounce System use.
对60名急性、亚急性或慢性肢体缺血症状患者进行的早期子集分析显示，96.8%的程序性血流恢复，81.7%的受试者在Pounce系统使用后未接受额外的血栓栓塞去除治疗。
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C.
Surmodics公司（纳斯达克股票代码：SRDX）是医疗保健行业中领先的医疗器械和体外诊断技术提供商，今天宣布了其PROWL登记研究中60名真实世界急性、亚急性和慢性肢体缺血患者的早期结果，由Dean Ferrera博士在华盛顿特区举行的第36届TCt研讨会上进行了报告。
